DDX53 and neoplasm: To address this challenge, we evaluated whether a combinational nano‐immunotherapy modulating the TIME via POx‐Man nanovaccine, anti‐PD‐1 monoclonal antibody (mAb), and TAM targeting, would control MC38 and CT26 tumor growth and survival.